AZ KLINA

Running trials

• Recruiting

  A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

  NCT07363044· Source

• Recruiting

  Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

  NCT06691425· Source

• Active, not recruiting

  Remote MS Care in Antwerp

  NCT06179758· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Recruiting

  Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

  NCT05701241· Phase 4· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Source

• Recruiting

  Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy

  NCT05169593· Phase 4· Source

• Recruiting

  FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients

  NCT07558083· Phase 3· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Source

• Active, not recruiting

  A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.

  2022-501485-22-00· Phase 3· Source

• Active, not recruiting

  ASPIRIN Trial Belgium

  NCT03464305· Phase 3· Source

• Active, not recruiting

  Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

  NCT01924819· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Colorectal cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors

  NCT05642780· Phase 2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Source

• Completed

  An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)

  NCT04941768· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Source